Jim Cramer Recommends CVS Health Stock, Citing Strong Market Position
Money

Jim Cramer Recommends CVS Health Stock, Citing Strong Market Position

authorBy Vicki Robin
DateJul 13, 2026
Read Time2 min

Financial expert Jim Cramer recently championed CVS Health Corporation (NYSE:CVS) as a compelling investment opportunity, urging individuals to acquire its shares. He underscored CVS's strategic edge, particularly its integration of Aetna, which he believes fortifies its position against competitors like Amazon. Cramer's endorsement comes amidst a period where the healthcare sector has faced headwinds, yet he sees CVS as poised for sustained growth.

Renowned Analyst Jim Cramer Endorses CVS Health, Citing Strategic Acquisitions and Market Leadership

On Monday, July 13, 2026, during an episode of his program, Jim Cramer, a well-known financial commentator, provided a decisive "buy" recommendation for CVS Health Corporation (NYSE:CVS). This advice was given in response to an inquiry about the future prospects of healthcare stocks, which have recently experienced a period of underperformance. Cramer's rationale for his strong endorsement centered on CVS's robust competitive standing within the pharmaceutical and healthcare retail landscape.

He pointed out the diminishing presence of traditional rivals such as Walgreens and Rite Aid, asserting that CVS's primary contemporary competitor is Amazon. However, Cramer highlighted CVS's significant advantage through its ownership of Aetna, emphasizing that "Aetna is crushing it." This strategic acquisition provides CVS with a unique integrated healthcare model, encompassing insurance, pharmacy benefit management, and retail pharmacy services, thereby setting it apart from potential disruptors.

Cramer also referenced his comments from a July 1 episode, where he expressed enthusiasm for the performance of health insurers and drug distributors. He specifically noted, "I bet the gains in CVS will be long-lasting," and voiced approval for other industry leaders like UnitedHealth and Humana, acknowledging their strong performance.

Despite his optimism for CVS, the article subtly introduces an alternative perspective, suggesting that certain AI stocks might offer superior upside potential with reduced risk. It advises readers interested in highly undervalued AI stocks, particularly those poised to benefit from current trade policies and reshoring trends, to consult a specialized report.

The discussion around CVS Health's investment appeal, particularly in the context of broader market trends and the emergence of AI stocks, offers valuable insights for investors. Cramer's emphatic support for CVS, rooted in its strategic consolidation and competitive dominance, highlights the importance of intrinsic company strengths in navigating fluctuating market conditions. However, the mention of AI's potential serves as a reminder for investors to continuously evaluate diverse sectors and emerging technologies for growth opportunities, balancing established players with innovative ventures for a well-rounded portfolio.

More Articles
Money
Software Showdown: Agilysys vs. HubSpot - An Investment Analysis for 2026
This article analyzes two prominent software companies, Agilysys and HubSpot, comparing their business models, financial performance, risk profiles, and valuations to determine which presents a more compelling investment opportunity for 2026. Agilysys specializes in hospitality software, while HubSpot offers a broad CRM and marketing platform. Both are navigating the integration of AI and striving for increased profitability amidst market shifts.
By Scott PapeJul 13, 2026
Money
Cybersecurity Acquisition Race: Tech Giants Eye SentinelOne's $6 Billion Value
Leading technology firms are vying for SentinelOne, a cybersecurity company valued at $6.1 billion, known for its robust balance sheet and growing annual recurring revenue. Cisco Systems appears to be the most fitting suitor, seeking to bolster its stagnant security segment, while Microsoft and Amazon face regulatory hurdles or prioritize organic growth, respectively. Alphabet also shows interest, aligning with its cloud expansion strategy. The acquisition of SentinelOne could significantly reshape the cybersecurity landscape.
By T. Harv EkerJul 13, 2026
Money
Memory Stock Downturn: SK Hynix's Weak Forecast Triggers Market Shake-Up
The memory and storage stock market experienced a significant decline on Monday morning following a pessimistic profit forecast for South Korean chipmaker SK Hynix for the second quarter of 2026. This outlook, which fell 8% below analyst consensus, has sent ripples through the industry, causing major players like Micron, SanDisk, and Western Digital to see their stock prices drop by 6%. The Roundhill Memory ETF (DRAM) also fell 9%, highlighting the market's sensitivity to major industry players' performance and forecasts.
By Chika UwazieJul 13, 2026
Money
Argan Inc. Positioned for Growth Amidst Surging Power Demands
ClearBridge Investments, in its Q2 2026 'SMID Cap Growth Strategy' commentary, highlighted Argan, Inc. (AGX) as a new addition to its portfolio. The company, specializing in construction and maintenance for the power generation market, is poised to capitalize on the increasing demand for electricity. Despite a recent dip, Argan's shares have shown significant growth over the past year, reflecting its strong market position in natural gas and solar power infrastructure.
By JL CollinsJul 13, 2026
Money
Tesla Stock Performance Post-Earnings: An Analysis
This report examines the projected trajectory of Tesla's stock following its upcoming earnings announcement on July 22, 2026. Despite an anticipated strong performance in the second quarter, driven by robust delivery figures and revenue growth, concerns linger regarding the stock's valuation and the emergence of SpaceX as a competing investment option for Elon Musk enthusiasts. The article delves into the potential for continued stock decline post-earnings, contrasting with historical trends.
By T. Harv EkerJul 13, 2026